PMID- 31541887 OWN - NLM STAT- MEDLINE DCOM- 20200513 LR - 20200513 IS - 1950-6007 (Electronic) IS - 0753-3322 (Linking) VI - 120 DP - 2019 Dec TI - The dual roles of autophagy in gliomagenesis and clinical therapy strategies based on autophagic regulation mechanisms. PG - 109441 LID - S0753-3322(19)33501-2 [pii] LID - 10.1016/j.biopha.2019.109441 [doi] AB - Autophagy, a self-digestion intracellular catabolic process, plays a crucial role in cellular homeostasis under conditions of starvation, oxidative stress and genotoxic stress. The capability of maintaining homeostasis contributes to preventing malignant behavior in normal cells. Many studies have provided compelling evidence that autophagy is involved in brain tumor recurrence and chemotherapy and radiotherapy resistance. Gliomas, as the primary central nervous system (CNS) tumors, are characterized by rapid, aggressive growth and recurrence and have a poor prognosis and bleak outlook even with modern multimodality strategies involving maximal surgical resection, radiotherapy and alkylating agent-based chemotherapy. Autophagy-associated signaling pathways, such as the extracellular signal-regulated kinase1/2 (ERK1/2) pathway, class I phosphatidylinositol 3-phosphate kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway and nuclear factor kappa-B (NF-kappaB) pathway, act as tumor suppressors or protect tumor cells against chemotherapy/radiotherapy-induced cytotoxicity in gliomagenesis. Through these pathways, both lethal autophagy and protective autophagy play crucial roles in tumor initiation, chemoresistance and glioma stem cell differentiation. Moreover, lethal autophagy and protective autophagy have been identified as novel therapeutic targets in glioma according to the mechanisms described above. Here, we discuss the multiple impacts of the autophagic response on distinct phases of gliomagenesis and the advanced progress of therapies based on this concept. CI - Copyright (c) 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved. FAU - Feng, Fan AU - Feng F AD - Institute of Clinical Medicine College, Qingdao University, # 38, Dengzhou Road, Qingdao 266071, Shandong, China. FAU - Zhang, Moxuan AU - Zhang M AD - Weifang Medical University, 261042, # 7166, Baotong Western Road, Weifang, Shandong, China. FAU - Yang, Chuanchao AU - Yang C AD - Weifang Medical University, 261042, # 7166, Baotong Western Road, Weifang, Shandong, China. FAU - Heng, Xueyuan AU - Heng X AD - Department of Neurosurgery, Linyi People's Hospital, # 27, Jiefang Eastern Road, Linyi 276000, Shandong, China. Electronic address: hengxuey001@163.com. FAU - Wu, Xiujie AU - Wu X AD - Department of Neurosurgery, Linyi People's Hospital, # 27, Jiefang Eastern Road, Linyi 276000, Shandong, China. Electronic address: wuxiuj001@163.com. LA - eng PT - Journal Article PT - Review DEP - 20190918 PL - France TA - Biomed Pharmacother JT - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JID - 8213295 SB - IM MH - Animals MH - Autophagy/*physiology MH - Brain Neoplasms/metabolism/physiopathology MH - Central Nervous System Neoplasms/metabolism/physiopathology MH - Glioblastoma MH - Glioma/*metabolism/*physiopathology MH - Humans MH - Neoplasm Recurrence, Local/physiopathology MH - Signal Transduction OTO - NOTNLM OT - Autophagy OT - Clinical therapy OT - GSCs OT - Gliomas OT - Signaling pathway EDAT- 2019/09/22 06:00 MHDA- 2020/05/14 06:00 CRDT- 2019/09/22 06:00 PHST- 2019/07/18 00:00 [received] PHST- 2019/09/02 00:00 [revised] PHST- 2019/09/06 00:00 [accepted] PHST- 2019/09/22 06:00 [pubmed] PHST- 2020/05/14 06:00 [medline] PHST- 2019/09/22 06:00 [entrez] AID - S0753-3322(19)33501-2 [pii] AID - 10.1016/j.biopha.2019.109441 [doi] PST - ppublish SO - Biomed Pharmacother. 2019 Dec;120:109441. doi: 10.1016/j.biopha.2019.109441. Epub 2019 Sep 18.